Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival

Antonio Galleu; Dragana Milojkovic; Simona Deplano; Richard Szydlo; Sandra Loaiza; Robert Wynn; David I. Marks; Deborah Richardson; Kim Orchard; Edward Kanfer; Eleni Tholouli; Muhammad Saif; Ponni Sivaprakasam; Sarah Lawson; Adrian Bloor; Antonio Pagliuca; Victoria Potter; Varun Mehra; John A. Snowden; Ajay Vora; Bhuvan Kishore; Hannah Hunter; Jane F. Apperley; Francesco Dazzi

doi:10.1111/bjh.15749

Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival

Antonio Galleu, Dragana Milojkovic, Simona Deplano, Richard Szydlo, Sandra Loaiza, Robert Wynn, David I. Marks, Deborah Richardson, Kim Orchard, Edward Kanfer, Eleni Tholouli, Muhammad Saif, Ponni Sivaprakasam, Sarah Lawson, Adrian Bloor, Antonio Pagliuca, Victoria Potter, Varun Mehra, John A. Snowden, Ajay VoraBhuvan Kishore, Hannah Hunter, Jane F. Apperley, Francesco Dazzi^*

^*Corresponding author for this work

Comprehensive Cancer Centre

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

112 Downloads (Pure)

Abstract

Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid‐resistant graft‐versus‐host‐disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. We show that clinical responses assessed as early as 1 week after MSC infusion predict patients’ overall survival. In our cohort, cell dose, patients’ age and type of organ involvement are crucial factors associated with clinical responses.

Original language	English
Pages (from-to)	89-92
Number of pages	4
Journal	British Journal of Haematology
Volume	185
Issue number	1
Early online date	13 Jan 2019
DOIs	https://doi.org/10.1111/bjh.15749
Publication status	Published - Apr 2019

Keywords

cellular therapies
clinical research
GvHD
mesenchymal cells
stromal cells

Access to Document

10.1111/bjh.15749Licence: CC BY

Mesenchymal stromal cells for_GALLEU_Accepted11December2018Publishedonline13January2019_GOLD VoR (CC BY)Final published version, 87.7 KBLicence: CC BY

http://eprints.whiterose.ac.uk/141257/

Cite this

Galleu, A., Milojkovic, D., Deplano, S., Szydlo, R., Loaiza, S., Wynn, R., Marks, D. I., Richardson, D., Orchard, K., Kanfer, E., Tholouli, E., Saif, M., Sivaprakasam, P., Lawson, S., Bloor, A., Pagliuca, A., Potter, V., Mehra, V., Snowden, J. A., ... Dazzi, F. (2019). Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival. British Journal of Haematology, 185(1), 89-92. https://doi.org/10.1111/bjh.15749

@article{1439cbece30a41499c014b51e29c33fd,

title = "Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival",

abstract = "Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid‐resistant graft‐versus‐host‐disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. We show that clinical responses assessed as early as 1 week after MSC infusion predict patients{\textquoteright} overall survival. In our cohort, cell dose, patients{\textquoteright} age and type of organ involvement are crucial factors associated with clinical responses.",

keywords = "cellular therapies, clinical research, GvHD, mesenchymal cells, stromal cells",

author = "Antonio Galleu and Dragana Milojkovic and Simona Deplano and Richard Szydlo and Sandra Loaiza and Robert Wynn and Marks, {David I.} and Deborah Richardson and Kim Orchard and Edward Kanfer and Eleni Tholouli and Muhammad Saif and Ponni Sivaprakasam and Sarah Lawson and Adrian Bloor and Antonio Pagliuca and Victoria Potter and Varun Mehra and Snowden, {John A.} and Ajay Vora and Bhuvan Kishore and Hannah Hunter and Apperley, {Jane F.} and Francesco Dazzi",

year = "2019",

month = apr,

doi = "10.1111/bjh.15749",

language = "English",

volume = "185",

pages = "89--92",

journal = "British Journal of Haematology",

issn = "1365-2141",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

Galleu, A, Milojkovic, D, Deplano, S, Szydlo, R, Loaiza, S, Wynn, R, Marks, DI, Richardson, D, Orchard, K, Kanfer, E, Tholouli, E, Saif, M, Sivaprakasam, P, Lawson, S, Bloor, A, Pagliuca, A, Potter, V, Mehra, V, Snowden, JA, Vora, A, Kishore, B, Hunter, H, Apperley, JF & Dazzi, F 2019, 'Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival', British Journal of Haematology, vol. 185, no. 1, pp. 89-92. https://doi.org/10.1111/bjh.15749

TY - JOUR

T1 - Mesenchymal stromal cells for acute graft‐versus‐host disease

T2 - response at 1 week predicts probability of survival

AU - Galleu, Antonio

AU - Milojkovic, Dragana

AU - Deplano, Simona

AU - Szydlo, Richard

AU - Loaiza, Sandra

AU - Wynn, Robert

AU - Marks, David I.

AU - Richardson, Deborah

AU - Orchard, Kim

AU - Kanfer, Edward

AU - Tholouli, Eleni

AU - Saif, Muhammad

AU - Sivaprakasam, Ponni

AU - Lawson, Sarah

AU - Bloor, Adrian

AU - Pagliuca, Antonio

AU - Potter, Victoria

AU - Mehra, Varun

AU - Snowden, John A.

AU - Vora, Ajay

AU - Kishore, Bhuvan

AU - Hunter, Hannah

AU - Apperley, Jane F.

AU - Dazzi, Francesco

PY - 2019/4

Y1 - 2019/4

N2 - Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid‐resistant graft‐versus‐host‐disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. We show that clinical responses assessed as early as 1 week after MSC infusion predict patients’ overall survival. In our cohort, cell dose, patients’ age and type of organ involvement are crucial factors associated with clinical responses.

AB - Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid‐resistant graft‐versus‐host‐disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. We show that clinical responses assessed as early as 1 week after MSC infusion predict patients’ overall survival. In our cohort, cell dose, patients’ age and type of organ involvement are crucial factors associated with clinical responses.

KW - cellular therapies

KW - clinical research

KW - GvHD

KW - mesenchymal cells

KW - stromal cells

UR - http://www.scopus.com/inward/record.url?scp=85059952854&partnerID=8YFLogxK

U2 - 10.1111/bjh.15749

DO - 10.1111/bjh.15749

M3 - Article

AN - SCOPUS:85059952854

SN - 1365-2141

VL - 185

SP - 89

EP - 92

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this